| Literature DB >> 28483460 |
Somenath Roy Chowdhury1, Ashish Kumar2, Joseane Lima Prado Godinho3, Sara Teixeira De Macedo Silva3, Aline Araujo Zuma3, Sourav Saha1, Neha Kumari1, Juliany Cola Fernandes Rodrigues3, Shyam Sundar4, Jean-Claude Dujardin5, Syamal Roy6, Wanderley De Souza3, Sibabrata Mukhopadhyay2, Hemanta K Majumder7.
Abstract
Indole alkaloids possess a large spectrum of biological activities including anti-protozoal action. Here we report for the first time that voacamine, isolated from the plant Tabernaemontana coronaria, is an antiprotozoal agent effective against a large array of trypanosomatid parasites including Indian strain of Leishmania donovani and Brazilian strains of Leishmania amazonensis and Trypanosoma cruzi. It inhibits the relaxation activity of topoisomerase IB of L. donovani (LdTop1B) and stabilizes the cleavable complex. Voacamine is probably the first LdTop1B-specific poison to act uncompetitively. It has no impact on human topoisomerase I and II up to 200μM concentrations. The study also provides a thorough insight into ultrastructural alterations induced in three kinetoplastid parasites by a specific inhibitor of LdTop1B. Voacamine is also effective against intracellular amastigotes of different drug unresponsive field isolates of Leishmania donovani obtained from endemic zones of India severely affected with visceral leishmaniasis. Most importantly, this is the first report demonstrating the efficacy of a compound to reduce the burden of drug resistant parasites, unresponsive to SAG, amphotericin B and miltefosine, in experimental BALB/c mice model of visceral leishmaniasis. The findings cumulatively provide a strong evidence that voacamine can be a promising drug candidate against trypanosomatid infections.Entities:
Keywords: Kinetoplastids; Topoisomerase IB; Ultrastructure; Voacamine
Mesh:
Substances:
Year: 2017 PMID: 28483460 DOI: 10.1016/j.bcp.2017.05.002
Source DB: PubMed Journal: Biochem Pharmacol ISSN: 0006-2952 Impact factor: 5.858